176 related articles for article (PubMed ID: 21559085)
21. Mammary tumor formation and metastasis evoked by a HER2 splice variant.
Alajati A; Sausgruber N; Aceto N; Duss S; Sarret S; Voshol H; Bonenfant D; Bentires-Alj M
Cancer Res; 2013 Sep; 73(17):5320-7. PubMed ID: 23867476
[TBL] [Abstract][Full Text] [Related]
22. An ErbB2 splice variant lacking exon 16 drives lung carcinoma.
Smith HW; Yang L; Ling C; Walsh A; Martinez VD; Boucher J; Zuo D; Sokol ES; Pavlick DC; Frampton GM; Chmielecki J; Jones LM; Roux PP; Lockwood WW; Muller WJ
Proc Natl Acad Sci U S A; 2020 Aug; 117(33):20139-20148. PubMed ID: 32727899
[TBL] [Abstract][Full Text] [Related]
23. Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer.
Castagnoli L; Ghedini GC; Koschorke A; Triulzi T; Dugo M; Gasparini P; Casalini P; Palladini A; Iezzi M; Lamolinara A; Lollini PL; Nanni P; Chiodoni C; Tagliabue E; Pupa SM
Oncogene; 2017 Mar; 36(12):1721-1732. PubMed ID: 27641338
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of miR-489 derails mammary hierarchy structure and inhibits HER2/neu-induced tumorigenesis.
Patel Y; Soni M; Awgulewitsch A; Kern MJ; Liu S; Shah N; Singh UP; Chen H
Oncogene; 2019 Jan; 38(3):445-453. PubMed ID: 30104710
[TBL] [Abstract][Full Text] [Related]
25. The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis.
Rudolph-Owen LA; Chan R; Muller WJ; Matrisian LM
Cancer Res; 1998 Dec; 58(23):5500-6. PubMed ID: 9850086
[TBL] [Abstract][Full Text] [Related]
26. Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice.
Landis MD; Seachrist DD; Montañez-Wiscovich ME; Danielpour D; Keri RA
Oncogene; 2005 Aug; 24(33):5173-90. PubMed ID: 15897883
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of activated murine Notch1 and Notch3 in transgenic mice blocks mammary gland development and induces mammary tumors.
Hu C; Diévart A; Lupien M; Calvo E; Tremblay G; Jolicoeur P
Am J Pathol; 2006 Mar; 168(3):973-90. PubMed ID: 16507912
[TBL] [Abstract][Full Text] [Related]
28. The nuclear receptor coactivator amplified in breast cancer-1 is required for Neu (ErbB2/HER2) activation, signaling, and mammary tumorigenesis in mice.
Fereshteh MP; Tilli MT; Kim SE; Xu J; O'Malley BW; Wellstein A; Furth PA; Riegel AT
Cancer Res; 2008 May; 68(10):3697-706. PubMed ID: 18483252
[TBL] [Abstract][Full Text] [Related]
29. Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice.
Muller WJ; Arteaga CL; Muthuswamy SK; Siegel PM; Webster MA; Cardiff RD; Meise KS; Li F; Halter SA; Coffey RJ
Mol Cell Biol; 1996 Oct; 16(10):5726-36. PubMed ID: 8816486
[TBL] [Abstract][Full Text] [Related]
30. The extracellular region of heregulin is sufficient to promote mammary gland proliferation and tumorigenesis but not apoptosis.
Weinstein EJ; Leder P
Cancer Res; 2000 Jul; 60(14):3856-61. PubMed ID: 10919660
[TBL] [Abstract][Full Text] [Related]
31. Loss of periostin/OSF-2 in ErbB2/Neu-driven tumors results in androgen receptor-positive molecular apocrine-like tumors with reduced Notch1 activity.
Sriram R; Lo V; Pryce B; Antonova L; Mears AJ; Daneshmand M; McKay B; Conway SJ; Muller WJ; Sabourin LA
Breast Cancer Res; 2015 Jan; 17(1):7. PubMed ID: 25592291
[TBL] [Abstract][Full Text] [Related]
32. Insertional mutagenesis in a HER2-positive breast cancer model reveals ERAS as a driver of cancer and therapy resistance.
Ikink GJ; Boer M; Bakker ERM; Vendel-Zwaagstra A; Klijn C; Ten Hoeve J; Jonkers J; Wessels LF; Hilkens J
Oncogene; 2018 Mar; 37(12):1594-1609. PubMed ID: 29326437
[TBL] [Abstract][Full Text] [Related]
33. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.
Kim A; Liu B; Ordonez-Ercan D; Alvarez KM; Jones LD; McKimmey C; Edgerton SM; Yang X; Thor AD
Breast Cancer Res; 2005; 7(5):R708-18. PubMed ID: 16168116
[TBL] [Abstract][Full Text] [Related]
34. In vivo evidence supporting a metastasis suppressor role for Stard13 (Dlc2) in ErbB2 (Neu) oncogene induced mouse mammary tumors.
Basak P; Leslie H; Dillon RL; Muller WJ; Raouf A; Mowat MRA
Genes Chromosomes Cancer; 2018 Apr; 57(4):182-191. PubMed ID: 29218825
[TBL] [Abstract][Full Text] [Related]
35. Transgenic mice expressing a dominant-negative mutant type II transforming growth factor-beta receptor exhibit impaired mammary development and enhanced mammary tumor formation.
Gorska AE; Jensen RA; Shyr Y; Aakre ME; Bhowmick NA; Moses HL
Am J Pathol; 2003 Oct; 163(4):1539-49. PubMed ID: 14507660
[TBL] [Abstract][Full Text] [Related]
36. Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice.
Guy CT; Muthuswamy SK; Cardiff RD; Soriano P; Muller WJ
Genes Dev; 1994 Jan; 8(1):23-32. PubMed ID: 7507074
[TBL] [Abstract][Full Text] [Related]
37. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling.
Brantley-Sieders DM; Zhuang G; Hicks D; Fang WB; Hwang Y; Cates JM; Coffman K; Jackson D; Bruckheimer E; Muraoka-Cook RS; Chen J
J Clin Invest; 2008 Jan; 118(1):64-78. PubMed ID: 18079969
[TBL] [Abstract][Full Text] [Related]
38. Deregulation of the Hippo pathway in mouse mammary stem cells promotes mammary tumorigenesis.
Li H; Gumbiner BM
Mamm Genome; 2016 Dec; 27(11-12):556-564. PubMed ID: 27601049
[TBL] [Abstract][Full Text] [Related]
39. Activated Akt1 accelerates MMTV-c-ErbB2 mammary tumourigenesis in mice without activation of ErbB3.
Young CD; Nolte EC; Lewis A; Serkova NJ; Anderson SM
Breast Cancer Res; 2008; 10(4):R70. PubMed ID: 18700973
[TBL] [Abstract][Full Text] [Related]
40. The transcription factor ATF3 acts as an oncogene in mouse mammary tumorigenesis.
Wang A; Arantes S; Yan L; Kiguchi K; McArthur MJ; Sahin A; Thames HD; Aldaz CM; Macleod MC
BMC Cancer; 2008 Sep; 8():268. PubMed ID: 18808719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
